ugn-301
Generic: zalifrelimab
ugn-301: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| UroGen Pharma Ltd. (URGN) | Phase 3 |
Clinical Trials (1)
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
Frequently asked questions
Who is developing ugn-301?
ugn-301 is being developed by UroGen Pharma Ltd..
How many clinical trials involve ugn-301?
BioSniper tracks 1 clinical trial involving ugn-301.
Get deeper analysis on ugn-301
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis